“This systematic review and meta-analyses confirms that blood pressure lowering treatment is associated with reduced mortality and cardiovascular morbidity in people with diabetes mellitus, if systolic blood pressure before treatment is more than 140 mm Hg,” the authors wrote. “If SBP is less than 140 mm Hg, however, we found no benefit, but potential harm, with an increased risk of cardiovascular death.”
The authors concluded that the most likely biological explanation for the findings is the impairment of organ blood flow that can stem from intensive treatment. They suggest that blood pressure treatment goals should be less aggressive for patients with diabetes.
More articles on quality:
Researchers mine EHR data to identify patients with undiagnosed diabetes
A look at healthcare in Freddie Gray’s Baltimore: 5 major takeaways
5 animals capable of detecting infections and diseases in humans
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.